Reviparin sodium – a new low molecular weight heparin

REFERENCES

• NICOLAIDES AN, BREDDIN HK, FAREED J et al.: Prevention of venous thromboembolism. International consensus statement. Guidelines compiled in accordance with the scientific evidence. Int. Angiol. (2001) 20:1–37.
   Google Scholar
• VOUYOUKA A, SILVER D: Is low-molecular-weight heparin the answer for the therapy of acute deep vein thrombosis? Vase. Surg. (1999) 33:125–128.
   Web of Science ®Google Scholar
• PINED GF, HULL RD: Low-molecular-weight heparin: prophylaxis and treatment of venous thromboembolism. Ann. Rev Med. (1997) 48:79–91.
   PubMed Web of Science ®Google Scholar
• HULL RD, PINEO GF, VALENTINE KA:Treatment and prevention of venous thromboembolism. Semin Thromb. Hemost. (1998) 24\(Suppl. 1):21–31.
   Google Scholar
• FAREED J, JESKE W, ESCHENFELDER V etal.: Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin. Semin Thromb. Hemost. (1995) 21:212–227.
   Google Scholar
• BONEU B: Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb. Res. (2000) 100: V113–V120.
   Google Scholar
• HOPPENSTEADT D, JESKE W, FAREED J: Pharmacological profile of reviparin-sodium. Blood Coagul. Fibnholysis (1993) 4\(Suppl. 1):S11–516.
   Google Scholar
• ANDRASSY K, ESCHENFELDER V, KODERISCH J et al.: Pharmacokinetics of Clivarine, a new low molecular weight heparin, in healthy volunteers. Thromb. Res. (1994) 73:95–108.
   PubMed Web of Science ®Google Scholar
• WEITZ JL: Low-molecular-weight heparins. N Engl. j Med. (1997) 337:688–698.
   PubMed Web of Science ®Google Scholar
• HIRSH J, WARKENTIN TE, RASCHKER et al.: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest (1998) 114(Suppl.):5489–5510.
   Google Scholar
• DESNOYERS PC, SAMAMA MM: Pharmacokinetics and metabolism of reviparin. Drugs Today (1995) 31 (Suppl. D):61–72.
   Google Scholar
• AZIZI M, VEYSSIER-BELOT C, ALHENC-GELAS M et al.: Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br. J. Clin. Pharmacol. (1995) 40:577–584.
   PubMed Web of Science ®Google Scholar
• BAUMELOU A, SINGLAS E, PETITCLERC T et al.: Pharmacokinetics of a low molecular weight heparin (reviparin) in hemodialyzed patients. Nephron (1994) 68:202–206.
   PubMed Web of Science ®Google Scholar
• RADZIWON E SCHENK J, BOCZKOWSKA-RADZIWON B, FAREED J, BREDDIN HK: TFPI release by GAGs and its role in their mechanism of action. In: Nortanticoagulant Actions of Clycosaminoglycarts. Harenberg J, Casu B (Eds.), Plenum Press, New York & London (1996):227–233.
   Google Scholar
• ABILDGAARD U: Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis (1993) 23\(Suppl. 1):103–106.
   Google Scholar
• BROZE GJ JR: Tissue factor pathway inhibitor. Thromb. Haemost. (1995) 74:90–93.
   PubMed Web of Science ®Google Scholar
• BERRETTINI M, ASCANI A, PARISE P et al.: The release of tissue factor pathway inhibitor (TFPI) in patients receiving prophylactic antithrombotic regimens with unfractioned heparin or LMWH (reviparin). Thromb. Haemost. (1997) (Suppl.):410-411. Abstract.
   Google Scholar
• KLINKHARDT U, BREDDIN HK, ESSLINGER HU et al.: Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br .j Clin. Pharmacol (2000) 49:337–341.
   PubMed Web of Science ®Google Scholar
• KLINKHARDT U, GRAFF J, WESTRUP D etal.: Pharmacodynamic character-ization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects. Br. j Clin. Pharmacol. (2001) 52:297–305.
   Google Scholar
• ANDRASSY K: Low molecular weight heparin and haemodialysis: neutralization by protaminchloride. Blood Coagul. Fibrinolysis (1993) 4\(Suppl. 1):S39–S43.
   Google Scholar
• HIRSH J, LEVINE MN: Low molecular weight heparin. Blood (1992) 79:1–17.
   PubMed Web of Science ®Google Scholar
• SAMAMA MM, BARA L, GOUIN T-I et al.: New data on the pharmacology of heparin and low molecular weight heparins. Drugs (1996) 52\(Suppl. 7):8–15.
   Google Scholar
• CROWTHER MA, SPITZER K, JULIAN J et al.: Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients: a prospective cohort study. Thromb. Res. (2000) 98:133–138.
   PubMed Web of Science ®Google Scholar
• GOTTSTEIN S, KLAMROTH R, HEINRICHS C: Low molecular weight heparin for prevention and treatment of venous thromboembolism in pregnancy. Ann. Hematol. (2000) 79\(Suppl. 1):A95. Abstract.
   Google Scholar
• LASKIN C, GINSBERG J, FARINE D et al.: Low molecular weight heparin and ASA therapy in women with autoantibodies and unexplained recurrent fetal loss. Am. Obstet. Cyriecol. (1997) 176:125. Poster.
   Google Scholar
• LASSEN MR, BORRIS LC, BACHER Pet al.: Efficacy and safety of low molecular weight heaprin (Clivarine) in the prophylaxis of venous thromboembolism in patients with brace immobilization after injury of the lower extremity. Blood (2000) 96:2113. Abstract.
   Google Scholar
• WIRTH T, SCHNEIDER B, MISSELWITZ F etal.: Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): results of a randomized controlled trial. Arthroscopy (2001) 17:393–399.
   Google Scholar
• KAKKAR VV, BOECKL 0, BONEU B et al.: Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World I. Surg. (1997) 21:2–8.
   Google Scholar
• PLANES A, VOCHELLE N, CHEVRET S et al: Dose-finding studies of reviparin in elective hip surgery. Semi]. Thromb. Hemost. (1993) 19\(Suppl. 1):44–48.
   Google Scholar
• PLANES A, VOCHELLE N, FAGOLA M et al.: Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul. Fibrinolysis (1998) 9:499–505.
   PubMed Web of Science ®Google Scholar
• SAMAMA CM, VRAY M, BARRE J et al.:Long-term venous thromboembolism prophylaxis after total hip replacement: a comparison of low molecular weight heparin with oral anticoagulant. Thromb. Haemost. (2001) (Suppl.):0C2343. Abstract.
   Google Scholar
• HAAS S, FAREED J, BREYER H-G, VICTOR N, BACHER P, MISSELWITZ F: for the ECHOS Investigators. Prevention of proximal deep vein thrombosis, pulmonary embolism and death in patients undergoing total hip or knee replacement. A double-blind trial comparing a low molecular weight heparin (reviparin) and unfractionated heparin. The ECHOS trial. Thromb. Haemost. (2001) (Suppl.):P2226. Abstract.
   Google Scholar
• KUJATH P, ECKMANN C, MISSELWITZ F: Low molecular weight heparin in arterial reconstructive surgery. A double-blind, randomized dose-finding trial. Thromb. Haemost. (2001) (Suppl.) T2310. Abstract.
   Google Scholar
• ANDREW M: A randomized control trialof low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Blood (2000) 96:492a. Abstract 2116.
   Google Scholar
• BOLLER HR, GENT M, GALLUS AS et al.: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The COLUMBUS Investigators. N Engl. j Med. (1997) 337:657–662.
   PubMed Web of Science ®Google Scholar
• BREDDIN HK, HACH-WUNDERLE V, NAKOV R etal.: Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl. J Med. (2001) 344:626–631.
   Google Scholar
• MARDER VJ, SOULEN RL, ATICHARTAKARN V et al.: Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. j Lab. Chit. Med. (1977) 89:1018–1029.
   PubMed Web of Science ®Google Scholar
• KARSCH KR, PREISACK MB, BAILDON R et al: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE J Am. Coll Cardiol. (1996) 28:1437–1443.
   PubMed Web of Science ®Google Scholar
• MASSICOTTE P, JULIAN JA, GENT M etal.: An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb. Haemost. (2001) (Suppl.): 0C969. Abstract.
   Google Scholar
• GALLUS AS: Thrombolytic therapy for venous thrombosis and pulmonary embolism. Baillieres Chit. Haematol (1998) 11:663–73.
   PubMedGoogle Scholar
• LOWE GDO, GREER IE, COOKE TG et al.: Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. Br Med. 1 (1992) 305:567-574.
   Google Scholar
• LECLERC JR, GEERTS WH, DESJARDINS L et al.: Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thremb. Haemest. (1992) 67:417–423.
   PubMed Web of Science ®Google Scholar
• BERGQVIST D, FLORDAL PA, FRIBERG B et al.: Thromboprophylaxis with a low molecular weight heparin (Tinzaparin) in emergency abdominal surgery. VASA (1996) 25:156–160.
   PubMedGoogle Scholar
• THE EUROPEAN FRAXIPARIN STUDY (EFS) GROUP: Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br I Sorg. (1988) 75:1058–1063.
   PubMed Web of Science ®Google Scholar
• LEIZOROVICZ A, PICOLET H, PEYRIEUX JC et al.: Prevention of perioperative deep vein thrombosis in general surgery: a multi-centre double-blind study comparing two doses of Logiparin and standard heparin. Br. 1. Sorg. (1991) 78:412–416.
   Google Scholar
• HULL R, RASKOB G, PINEO G et al.: Acomparison of sc. low-molecular-heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl. 1. Med. (1993) 329:1370–1376.
   Google Scholar
• LEVINE M, GENT M, HIRSH J etal.: Acomparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl. 1. Med. (1996) 334:677–681.
   Google Scholar
• KOOPMAN MMW, PRANDONI P, PIOVELLA F et al.: Treatment of venous thrombosis with iv. unfractionated heparin administered in the hospital as compared with sc. low-molecular-weight heparin administered at home. N Engl. I Med. (1996) 334:682–687.
   Google Scholar
• HULL RD, RASKOB GE, PINEO GF et al.: Subcutaneous low-molecular weight heparin compared with continuous iv. heparin in the treatment of proximal-vein thrombosis. N Engl. 1. Med. (1992) 326:975–982.
   Google Scholar
• KIRCHMAIER CM, WOLF H, SCHAFER H, EHLERS B, BREDDIN HK: Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with iv. unfractionated heparin in the treatment of deep venous thrombosis. Int. Angel. (1998) 17:135–145.
   Google Scholar